Local Covid-19 drugmaker CureVac has firmed up its executive team in advance of its much-anticipated IPO.
CureVac, which is based in Germany with U.S. headquarters in Boston, announced Tuesday that Dr. Franz-Werner Haas will become its permanent CEO. He stepped into the role on a temporary basis in March after a week in which CureVac went through two chief executives.
The company has also lured Igor Splawski over from the Novartis Institutes for Biomedical Research in Cambridge to serve as…
Boston Biz Journal https://www.bizjournals.com/boston/news/2020/08/04/curevac-nabs-novartis-exec-finalizes-ceo-during.html?ana=RSS&s=article_search